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sion of MDM2 and p53 mRNA and could not detect dif-
ferent MDM2 mRNA levels based on the MDM2-309
genotype, suggesting that MDM2 levels are controlled
independently in CLL. 
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A possible role for low-dose cyclosporine in 
refractory immune thrombocytopenic 
purpura
Management of patients with severe, refractory, chron-
ic immune thrombocytopenic purpura (ITP) is still diffi-
cult. However, although there is no consensus on the best
treatment strategy, these patients show a persistent,
marked thrombocytopenia, and need therapy, owing to
the presence of or to an increased risk of bleeding.
Various treatments have been attempted: immunosup-
pressive chemotherapy, high-dose dexamethasone, dana-
zol, combination chemotherapy, which have shown tran-
sient response in a variable percentage of cases, but none
with any evidence of safe and durable efficacy.1 Recently,
a systematic review of more than 300 patients treated
with a monoclonal anti-CD20 antibody, rituximab, many
of whom with a severe form of ITP, has shown an over-
all platelet response of 62.5%, a median response dura-
tion of 10.5 months, but also significant toxicities.
Therefore, the optimal timing and dose of the drug
remain undefined.2 More recently, good results have been
reported with a multiagent induction and maintenance
therapy, even if the duration of response was not
defined.3 Furthermore, an increase in platelet counts has
been obtained using a thrombopoietin-receptor agonist,
eltrombopag, though the durability of the response and
the long-term safety of this compound are unknown.4
Finally, a promising further approach  seems to be the
active and safe use of low dose rituximab.5 As reported in
published data, there are considerable side-effects associ-
ated with the current treatment and the responses of  var-
ious therapies have not yet been consolidated. Other
therapeutic strategies should, therefore, also be consid-
ered. There are few data in the literature describing the
effects of cyclosporine (CyA) therapy in this setting. A
study has been reported in adults in whom high toxicity
offsets benefits,6 and this finding has also been confirmed
in children.7 However, in both studies high doses of CyA
(5-10 mg/kg/d) have been used. 
We have already reported on long-term salvage thera-
py with CyA in 12 severe, refractory, chronic ITP8 with
83.3% of response (10/12), lasting for a median follow-
up of 36.8 months. The patients were 9 women and 3
men (median age 66.6 years, range 42-85 years). All
patients had previously received  2-3 drug therapies and
8 patients had also undergone splenectomy. Only
patients with platelet counts less than 30×109/L entered
the study. All patients had major or minor bleeding
episodes, often transient, but recurrent. Results of a long-
term follow-up of the responsive patients are shown in
Table 1. The updated median follow-up of approximate-
ly 5.5 years (69 months, range 4-13 years),  shows that 9
patients had maintained response for the duration of the
observation period (Figure 1). A further patient, not con-
sidered for the follow-up (n.8) died in complete remission
of myocardial infarction during a 3-month course of CyA
treatment. Five patients (ns. 1,2,7,9,and 10) had a com-
plete response (platelet counts in normal range), one
patient (n. 5) had a partial response (platelet counts
between 80 and 150x109/L), and 2 patients (ns. 3 and 12)
had a complete response which had been maintained
with continued drug administration. One patient (n. 4)
had a drug-dependent complete response  for approxi-
mately 4.5 years and a partial response for a further 1.5
year, after CyA had been tentatively discontinued and
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then restored. Two patients (ns. 10 and 4) had a relapse
at 5 and 6.5 years, respectively, and 1 patient (n. 3) died
at seven years. The drug dose was 2.5-3 mg/kg/d, after a
starting dose of 5 mg/kg/d for six days, to maintain a
therapeutic serum level between 200 and 400 ng/mL.
Patient monitoring included monthly blood cell counts
and examination of CyA serum level, renal and hepatic
functions every week for one month, then every two
months and every six months, after a stable remission
had been achieved. Platelet counts usually began to
increase after 3-4 weeks of treatment. A  further reduc-
tion of daily dose of CyA could be obtained by the co-
administration of grapefruit juice. The side-effects were
minor, transient and reversible, even after long-term,
continued treatment. Intolerance manifestations usually
resolved spontaneously or with a dose reduction of CyA
or its withdrawal for a few days. Only an infectious
episode (candidiasis, pt. n. 7) was recorded, which was
rapidly resolved by standard antifungal therapy and dis-
continuation of CyA for few days. Only one patient (n. 3)
showed a creatinine increase exceeding 150% of the
baseline value, resolved by a CyA dose reduction of 25%
for ten days. Similar results were recently obtained in
adults, in a smaller series with shorter follow-up, by oth-
ers9 and also in children.10 Furthermore, CyA has recent-
ly been recommended as a second-line therapy in Evans’
syndrome.11
The persistently high rate of responses, and the low
and transient toxicities, recorded after such a long-term
follow-up, suggest that the oral administration of low-
dose CyA, could be considered in severe, refractory ITP
as a salvage therapy and/or as a maintenance treatment
after a response has been obtained by rituximab or more
aggressive approaches.
We have been using this approach in  our current clin-
ical practice and believe that the debated issue of CyA-
related toxicity largely relies on the use of higher doses of
the drug and can be otherwise easily managed by the use
of standard or even lower doses of the drug and by a rou-
tine assessment of patients’ clinical and laboratory
parameters. Therefore, we encourage further studies on
larger series of patients to assess the general relevance of
our findings. We also suggest that patients with refracto-
ry ITP, screened positive for Helicobacter pylori (Hp) infec-
Table 1. Responsive patients’ characteristics.
Patient n. Previous Platelets (x109/L) Bleeding CyA 
therapies before CyA before CyA complications
1 P,G,A,Sple 15 ++ Fatigue, hypertension
2 P,G,ALG,Sple 29 ++ Gingival hyperplasia
3 P,G,ALG,Sple 18 + Hypertrichosis,
increased
creatinine
4 P,G,A,Sple 20 ++ Hypertension, Fatigue
5 P,G,C,Sple 10 ++ Gingival 
hyperplasia, tremor
7 P,G,C 28 ++ Hypertension,
candidiasis
9 P,G,C 27 ++ Gingival hyperplasia
10 P,G,Sple 12 ++ Myalgia
12 P,G,C 25 + Paresthesias
P: indicates prednisone; G: γ-globulins; A: azathioprine; ALG: antilymphocyte
globulin; C: cyclophosphamide; Sple: splenectomy. ++ indicates major bleeding
(diffuse ecchymosis and/or intrabuccal hemorrhagic vesicles, prolonged epistaxis,
menorrhagia, gastrointestinal, and/or genitourinary bleeding); + indicates minor
bleeding (mild purpura, mild epistaxis, gingival bleeding, easy bruising).                   
Figure 1. Updated long-term
follow-up of platelet counts
in patients treated with CyA.
Follow-up from April 1994 to
May 2007. Each small num-
ber is referred to one
responsive patient identified
by number in the previous
report.8 The bars indicate
the time of CyA administra-
tion. Patients ns. 3 and 12
had maintained response
with continued administra-
tion of CyA. In patient n. 4 a
decrease of platelet counts
was noted when CyA had
been tentatively discontin-
ued. In patient n. 3, a
decrease in platelet counts
was found concomitantly
with administration of
felodipine.  
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tion should undergo bacterium eradication before or after
CyA as reported,12 at least in areas with a high prevalence
of Hp infection.
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IgM anti-protein S antibodies as a risk factor
for venous thrombosis
Lupus anticoagulant (LA) and antiphospholipid antibod-
ies (APA) are immunoglobulins directed at phospholipid-
protein complexes that have been associated frequently
with thrombophilia. Protein S (PS) is a protein with high
affinity for phospholipids and can be a target for APA. It is
a cofactor in the Protein C (PC) anticoagulant pathway and
facilitates the inactivation of coagulation Factors Va and
VIIIa. We performed a case-control study to assess the
prevalence of anti-protein S antibodies (anti-PS) in a
Spanish population and to determine if they are a risk fac-
tor for venous thrombosis (VT). 
Patients were included when they had been referred to
our hospital from November 1997 to April 2002. This
case-control study has been described previously in detail.1
Briefly: from the initial case-control study that included
250 patients and 250 controls, we obtained plasma for
anti-PS analysis from 244 patients (108 males, 136
females) and 246 controls (107 males, 139 females). The
patients were included in the study if they had suffered
their first thrombotic event when under 70 years of age.
Patients’ clinical characteristics are shown in Table 1. The
control subjects were recruited according to the following
criteria: similar age (±10 years), same sex, no genetic rela-
tionship to the patients and no personal or family history
of VT. All procedures were approved by the Institutional
Review Board of the Hospital de la Santa Creu i Sant Pau
in Barcelona. Written informed consent was obtained from
all participants.
Blood samples were obtained at least six months after
the most recent thombotic event. IgG and IgM anti-PS
antibodies were determined by an ELISA kit from Hyphen
BioMed (Neuville-sur-Oise), specific for the IgG or IgM
isotype. Normal range ≤8.2 AU for IgM and ≤8.9 AU for
IgG (99th percentile of the distribution in the control popu-
lation). The variation coefficient according to the manufac-
turer ranged from 3 to 6% for intra-assay and 4 to 8% for
inter-assay. Tests for LA used Russell viper venom, (Life
Diagnostics Frenchs Forest NSW Australia). IgG and IgM
APA, including anticardiolipin, antiphosphatidylserine and
anti-β2 Glycoprotein I were determined by ELISA meth-
ods. Antithrombin, PC, activated protein C resistance,
total and free PS, Factor VIII clotting activity, Factor V
Leiden (FVL), PT20210A of prothrombin gene, and
F12C46T polymorphism were analyzed as previously
described.1 Age was expressed as mean ± standard error
(SE). The frequencies of variables are expressed in percent-
ages and were compared with the χ2 test. A logistic regres-
sion method was used to estimate both the crude and
adjusted Odds Ratio (OR) as a measure of risk.
Adjustments were made for sex, age, LA and for other
APA as covariables.  Also, adjustments were made for
those factors previously associated with VT in our popula-
tion including: FVL, PT20210A, F12C46T (T/T), and levels
of FVIII >90th percentile. The SPSS 14.0 software package
was used for statistical analyses.
We found that 12 patients (4.9%) and 2 controls (0.8%)
had IgM anti-PS antibodies. The associated thrombotic
risk was 6.3 (95% CI: 1.4-28.5). After including LA and
APA as covariables, the adjusted OR was 6.1 (95% CI: 1.3-
28.0) (Table 2). The risk did not change when other throm-
botic risk factors were included in the analysis (adjusted
OR: 7.0; 95% CI: 1.5-33.5). After excluding patients with
recurrent thrombosis, we studied 183 patients; 8 of them
(4.4%) had IgM anti-PS. The associated risk was similar;
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